Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
May 11, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $88.6 million, representing 8% growth over the prior year quarter Nearing completion of new REGENERATE data analyses; planning for potential pre-submission meeting...
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
May 05, 2022 07:17 ET
|
Intercept Pharmaceuticals, Inc.
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of...
Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
May 02, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
March 02, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva...
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
February 23, 2022 08:49 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
December 20, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
December 09, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
November 15, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases Results will be featured in a...
Intercept to Present at Upcoming Investor Conferences
November 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...